Thermo Fisher Scientific Inc. agreed to acquire rival laboratory equipment manufacturer Life Technologies Corp. for $13.6 billion in cash and assumed debt on April 15. The target’s stockholders will receive $76 a share, a 38 percent premium to Life Technologies’s closing price on January 17, the day before it announced that it was engaging in a strategic review.
The companies hope to close the deal early next year pending approvals from regulators and Life Technologies shareholders.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
